Melanin concentrating hormone receptor antagonists

Details for Australian Patent Application No. 2004266228 (hide)

Owner Amgen, Inc.

Inventors Hulme, Christopher; Tempest, Paul; Ma, Vu

Agent EF WELLINGTON & CO

Pub. Number AU-A-2004266228

PCT Pub. Number WO2005/019240

Priority 60/494,855 13.08.03 US

Filing date 11 August 2004

Wipo publication date 3 March 2005

International Classifications

C07D 207/06 (2006.01) Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom

A61K 31/40 (2006.01) - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Event Publications

2 February 2006 PCT application entered the National Phase

  PCT publication WO2005/019240 Priority application(s): WO2005/019240

6 April 2006 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 10 Jan 2006

10 March 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004266232-Mitotic kinesin inhibitors

2004266227-4-cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists